RxDoctor Payments Data

David Hancock, MD

Family Medicine · Johnson City, TNNPI 1194753459

Payments from drug & device makers

$1,229in general payments, 2019–2025

Across 39 payments — averaging $31.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$327
  • Acadia Pharmaceuticals Inc$143
  • Sumitomo Pharma America, Inc.$125
  • Teva Pharmaceuticals USA, Inc.$121
  • Astellas Pharma US Inc$95
  • Novartis$56
  • plus $362 from 12 others

What the payments were for

  • Food & beverage$1,12992%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,229 in reported general payments places this provider in the 60th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$64,431
Medicare patients
277
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban744$182,422
TrulicityDulaglutide91$42,183
XeljanzTofacitinib Citrate28$31,179
JardianceEmpagliflozin86$28,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$26,143
NuedextaDextromethorphan Hbr/Quinidine43$24,849
GemtesaVibegron129$23,985
XareltoRivaroxaban76$23,877
RytaryCarbidopa/Levodopa27$13,410
BrilintaTicagrelor71$13,168
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,700
MyrbetriqMirabegron61$11,619
TradjentaLinagliptin64$11,371
Levothyroxine Sodium1,274$9,515
Xtampza ErOxycodone Myristate12$8,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz$33$213,600772 claims
Lilly USA, LLCTrulicity$19$42,18391 claims
AstraZenecaBrilinta, Breztri Aerosphere$50$24,86888 claims
Avanir Pharmaceuticals, Inc.Nuedexta$42$24,84943 claims
Sumitomo Pharma America, Inc.Gemtesa$125$23,985129 claims
Johnson & JohnsonXarelto$327$23,87776 claims
Astellas Pharma US IncMyrbetriq$95$11,61961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →